Ibutilide Fumarate and Nexterone

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using amiodarone together with ibutilide can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should notify your doctor immediately if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone. In addition, you should let your doctor know if you experience signs of electrolyte disturbance such as weakness, tiredness, drowsiness, confusion, muscle pain, cramps, dizziness, nausea, or vomiting. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADJUST DOSING INTERVAL: Class III antiarrhythmic agents and ibutilide have additive effects and may prolong cardiac refractoriness and increase the risk of arrhythmias. Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).

MANAGEMENT: Class III antiarrhythmic agents should not be given concomitantly with ibutilide (which also has class III properties) or within four hours after ibutilide is given. In clinical trials, other class III antiarrhythmic agents were withheld for at least five half-lives prior to ibutilide infusion and for four hours after dosing, but thereafter were allowed at the doctor's discretion.

Ibutilide Fumarate

Generic Name: ibutilide

Brand name: Corvert

Synonyms: Ibutilide

What is Ibutilide Fumarate?

Nexterone

Generic Name: amiodarone

Brand name: Nexterone, Pacerone, Cordarone

Synonyms: n.a.

What is Nexterone?